UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
__________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 19, 2008
AngioDynamics,
Inc.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
000-50761
|
11-3146460
|
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
603
Queensbury Avenue, Queensbury, New
York
12804
|
|
(Address of Principal Executive
Offices)
(Zip Code)
|
|
(518)
798-1215
|
|
(Registrant’s
telephone number, including area code)
|
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2 (b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4 (c))
|
Item
5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On
February 19, 2008, the Company announced that Robert D. Mitchell, the Company’s
Chief Operating Officer, has resigned his position effective February 29, 2008
to become the Chief Executive Officer of Nellix Endovascular, a start-up medical
device company.
A
copy of the press release issued by the Company on February 19, 2008, announcing
the resignation of Mr. Mitchell is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press
Release dated February 19, 2008.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ANGIODYNAMICS,
INC.
|
||
|
(Registrant)
|
||
|
Date:
February 19, 2008
|
By:
|
/s/
Joseph Gersuk
|
|
Joseph
Gersuk
Chief
Financial Officer
|
||
EXHIBIT
INDEX
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press
Release dated February 19, 2008.
|
|
EXHIBIT
99.1
FOR
IMMEDIATE RELEASE
|
Company
Contact:
|
Investor
Relations Contacts:
|
Media
Contact:
|
|
AngioDynamics,
Inc.
|
EVC Group,
Inc.
|
EVC Group,
Inc.
|
|
D.
Joseph Gersuk, CFO
|
Julie
Huang/Doug Sherk
|
Steve
DiMattia
|
|
(800)
772-6446 x1608
|
(646)
443-6963
|
(646)
201-5445
|
|
jgersuk@AngioDynamics.com
|
jhuang@evcgroup.com
|
sdimattia@evcgroup.com
|
|
dsherk@evcgroup.com
|
AngioDynamics
Announces Departure of COO Robert Mitchell
Mitchell
Accepts CEO Position of Start-up Medical Device Company
QUEENSBURY, N.Y. February 19, 2008—AngioDynamics (NASDAQ:
ANGO), a leading provider of innovative medical devices used by
interventional radiologists, nephrologists, and surgeons for the minimally
invasive treatment of cancer and peripheral vascular disease, announced today
that Robert D. Mitchell, the Company’s Chief Operating Officer, has resigned his
position effective February 29, 2008 to become the CEO of Nellix Endovascular, a
start-up medical device company.
“I
thank Bob Mitchell for his efforts and contributions over the past 14 months and
wish him well as he pursues the next chapter of his career,” said Eamonn Hobbs,
President & CEO. “Over the past year, we have strengthened our
senior management team. While I will be assuming many of Bob’s
responsibilities, others will add some responsibilities. We expect a
smooth transition and a continuation of our recent positive
momentum.”
About
AngioDynamics
AngioDynamics,
Inc. is a leading provider of innovative medical devices used by interventional
radiologists, surgeons, and other physicians for the minimally invasive
treatment of cancer and peripheral vascular disease. The Company's diverse
product line includes market-leading radiofrequency ablation systems, vascular
access products, angiographic products and accessories, dialysis products,
angioplasty products, drainage products, thrombolytic products, embolization
products and venous products. More information is available at www.angiodynamics.com.
Safe
Harbor
The
statements made in this document contain certain forward-looking statements that
involve a number of risks and uncertainties. Words such as "expects," "intends,"
"anticipates," "plans," "believes," "seeks," "estimates," or variations of such
words and similar expressions, are intended to identify such forward-looking
statements. Investors are cautioned that actual events or results may differ
from the Company's expectations. In addition to the matters described above, the
ability of the Company to develop its products, future actions by the FDA or
other regulatory agencies, results of pending or future clinical trials, overall
economic conditions, general market conditions, market acceptance, foreign
currency exchange rate fluctuations, the effects on pricing from group
purchasing organizations and competition, as well as the risk factors listed
from time to time in the SEC filings of AngioDynamics, Inc., including but not
limited to its Annual Report on Form 10-K for the year ended June 2, 2007, may
affect the actual results achieved by the
Company.